XGNExagen, Inc.

NAS · US · Healthcare · Diagnostics & Research · exagen.com

7.920USD+6.59%Mkt Cap: 191.86M $P/E: —3d ago

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and m…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

$44.91BUSDP/E 31.9

IDXX

IDEXX Laboratories, Inc.

Mettler-Toledo International, Inc.

$27.96BUSDP/E 31.5

Labcorp Holdings Inc.

$27.28BUSDP/E 27.8

DGX

Quest Diagnostics Incorporated

$26.97BUSDP/E 26.0

Guardant Health, Inc.

$22.91BUSD

MEDP

Medpace Holdings, Inc.

$17.33BUSDP/E 36.4

ERF

Eurofins Scientific SE

$13.65BUSDP/E 25.3

CRL

Charles River Laboratories International, Inc.

$14.09BUSD

RVTY

Revvity Inc. Common Stock

$13.92BUSDP/E 59.7

ICLR

ICON Public Limited Company

Twist Bioscience Corp.

$9.13BUSD

Key Statistics

Company

Market Cap191.86M $

Enterprise Value191.54M $

Revenue (TTM)71.12M $

Gross Profit38.80M $

Net Income (TTM)-19.95M $

Revenue/Share3.007 USD

Last Price7.920 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees216

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISINUS30068X1037

Valuation

P/E (Trailing)—

P/E (Forward)-17.68

PEG—

EV/EBITDA-17.78

EV/Revenue2.69

P/S2.65

P/B15.41

EPS (TTM)-0.86

EPS (Forward)-0.44

52W Range

2.59055% of range12.23

52W High12.23 USD

52W Low2.590 USD

Profitability

Gross Margin58.28%

Oper. Margin-8.63%

EBITDA Margin-15.15%

Profit Margin-29.97%

ROE-114.34%

ROA-34.39%

Growth

Revenue Growth15.90%

Earnings Growth—

Cash Flow & Leverage

Operating CF-13.63M $

CapEx (TTM)641.00K $

FCF Margin-2.19%

FCF Yield-0.81%

Net Debt3.07M $

Net Debt/EBITDA-0.28

Balance Sheet

Debt/Equity1.47

Current Ratio3.19

Quick Ratio2.75

Book Value/Sh0.5050 USD

Cash/Share1.015 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)9.857 USD

Upside (mean)+24.5%

Target Range9.000 USD – 12.00 USD

$9.000+24.5% to mean$12.00

# Analysts7

Ownership

Shares Out.24.23M

Float13.87M

Insiders27.83%

Institutions44.88%

Short Interest

Short Ratio4.1d

Short % Float4.12%

Short % Out.3.73%

Shares Short903.88K

Short (prev mo.)813.37K

Technical

SMA 505.114 (+54.9%)

SMA 2004.904 (+61.5%)

Beta2.03

S&P 52W Chg18.16%

Avg Vol (30d)376.70K

Avg Vol (10d)376.42K

Technical Indicators

RSI (14)79.4

MACD0.7172

MACD Signal0.5713

MACD Hist.+0.1459

BB Upper8.275 USD

BB Middle5.928 USD

BB Lower3.581 USD

BB Width79.19%

ATR (14)0.4493 USD

Vol Ratio (20d)0.56x